Stay On Top of New Treatments for Ulcerative Colitis
January 2024
You’ll see two new options for adults with moderate to severe ulcerative colitis (UC), mirikizumab (Omvoh) and upadacitinib (Rinvoq).
Injectable mirikizumab is the first anti-interleukin biologic approved for moderate to severe UC. Other anti-interleukin biologics, ustekinumab (Stelara) and risankizumab (Skyrizi), are approved for Crohn’s.
Oral upadacitinib is a Janus kinase (JAK) inhibitor used for arthritis (rheumatoid, etc). Now it’s approved for moderate to severe UC...similar to the other JAK inhibitor, tofacitinib (Xeljanz, etc).
Get concise advice on drug therapy, plus unlimited access to CE
Pharmacist's Letter Canada includes:
- 12 issues every year, with brief articles about new meds and hot topics
- 200+ CE courses, including the popular CE-in-the-Letter
- Quick reference drug comparison charts
- Access to the entire archive